Swedish company carries out research in metagenomics
BioGaia is to invest SEK12m (â‚¬1.3m; ÂŁ1.03m) in MetaboGen, located in Gothenburg, Sweden with the aim of developing the next-generation of probiotic products using new technology.
The investment will be made over a two-year period and will then give BioGaia a 35% stake in the company. BioGaia's President, Peter Rothschild, will become Chairman of MetaboGen.
MetaboGen, founded in 2011 by Professor Fredrik BĂ¤ckhed at the University of Gothenburg and Professor Jens B Nielsen at Chalmers University of Technology together with GU Holding, commercialises research and spins out companies linked to the University of Gothenburg. The company researches in metagenomics, the intensive and fast-developing field of gene sequencing in the microbial communities of, for example, the human gut to find previously unknown members and patterns of the microbial diversity related to health and disease.
The aim is to develop new treatments and products for different metabolic and other microbial associated diseases by influencing large parts of the microbiota.
The aim is to develop new treatments and products for different metabolic and other microbial associated diseases
The MetaboGen proprietary research platform is based on the pioneering work by BĂ¤ckhed's and Nielsen's research teams. Both men are active in the company and manage two research teams at their respective universities.
'I am very pleased that we are deepening our interesting collaboration with Prof. Fredrik BĂ¤ckhed and now also with Prof. Jens B Nielsen and their research teams, aiming to develop the next generation of probiotic products that could be possible with the help of this new and advanced technology,' said Rothschild, CEO of BioGaia.
'The fit with BioGaia as an investor in MetaboGen is perfect for the future. Our research coupled with BioGaiaâ€™s knowledge and experience in developing and marketing microbial based products is a unique combination that has high likelihood of success,' added BĂ¤ckhed.